Research group - Katalin Dobra
We study the differentiation of malignant tumors of the lung and pleura and their molecular signature relating to biological properties such as proliferation and invasion. We identify biomarkers that allow early diagnosis and optimize conditions for individualized treatment.
Research group leader Katalin Dobra
|Katalin Dobra||Senior lecturer/senior physician|
|Ghazal Heidari Hamedani||PhD student|
|Carl-Olof Hillerdal||PhD student|
|Anders Hjerpe||Professor emeritus|
|Joman Javadi||R&D trainee|
|Ashish Kumar Singh||Graduate Student|
- Cell culture, establishment of primary cells
- Molecular- and biochemical analyzes
- Lighting and fluorescence microscopy
- Ex-vivo susceptibility testing of primary tumor cells for cytotoxic substances and drugs
Research Council, the Swedish Cancer Society, AFA insurance, Heart-Lung Foundation, the Cancer Society in Stockholm, the Swedish Medical Society, Stockholm County Council (Research Fellow), KI Funds, Compass
We actively participate in the education of Medical- and Dental Student Programs and the Biomedical Analytical program
Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.
Cell. Signal. 2015 Oct;27(10):2054-67
Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
BMC Cancer 2014 Sep;14():709
Nuclear translocation of heparan sulfate proteoglycans and their functional significance.
Biochim. Biophys. Acta 2014 Aug;1840(8):2491-7
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mol. Cell Proteomics 2014 Mar;13(3):701-15